Sonrotoclax, Zanubrutinib and Rituximab in Previously Untreated Patients With Follicular Lymphoma
NCT07550855
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
52
Enrollment
OTHER
Sponsor class
Conditions
Follicular Lymphoma (FL)
Interventions
DRUG:
Sotoclax in combination with zanubrutinib and rituximab regimen
Sponsor
Sun Yat-sen University